2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T65d,Belapectin reduced variceal development in a subgroup of patients with MASH cirrhosis. We report the efficacy and safety of belapectin in patients with MASH cirrhosis and portal hypertension without varices at baseline. NAVIGATE was a global phase 2b trial. Patients were randomized to intravenous (i.v.) belapectin 2 or 4 mg/kg lean body weight or placebo for 18 months, stratified by type 2 diabetes. The primary endpoint was the incidence of varices with esophagogastroduodenoscopy (EGD) or a composite endpoint (new varices, intercurrent events, or discontinuation) at 18 months with belapectin versus placebo in the full analysis set (FAS). In a pre-specified analysis, new varices were evaluated in all patients who underwent EGD at baseline and 18 months. The per-protocol (PP) population was patients treated for 18 months with EGD at 18 months. Of 357 randomized patients, 291 completed treatment. Baseline characteristics were comparable across cohorts. In the FAS, 17.8% with placebo versus 10.1% with belapectin 2 mg/kg developed varices, a 43.2% reduction ( p =0.13). In the per-protocol population (PP), varices occurred in 22.3% with placebo versus 11.3% with belapectin 2 mg/kg, a 50% reduction (unadjusted p =0.04). Belapectin 4 mg/kg had no significant effect on variceal development. For the composite endpoint at 18 months, no significant difference was observed between belapectin 2 mg/kg ( p =0.14) or 4 mg/kg ( p =0.261) and placebo in the FAS. Belapectin was well-tolerated with no safety signals. Belapectin 2 mg/kg lowered the development of new varices in MASH cirrhosis and portal hypertension.31:T9a5, Background and Aims: Belapectin reduced variceal development in a subgroup of patients with MASH cirrhosis. We report the efficacy and safety of belapectin in patients with MASH cirrhosis and portal hypertension without varices at baseline. Approach and Results: NAVIGATE was a global phase 2b trial. Patients were randomized to intravenous (i.v.) belapectin 2 or 4 mg/kg lean body weight or placebo for 18 months, stratified by type 2 diabetes. The primary endpoint was the incidence of varices with esophagogastroduodenoscopy (EGD) or a composite endpoint (new varices, intercurrent events, or discontinuation) at 18 months with belapectin versus placebo in the full analysis set (FAS). In a pre-specified analysis, new varices were evaluated in all patients who underwent EGD at baseline and 18 months. The per-protocol (PP) population was patients treated for 18 months with EGD at 18 months. Of 357 randomized patients, 291 completed treatment. Baseline characteristics were comparable across cohorts. In the FAS, 17.8% with placebo versus 10.1% with belapectin 2 mg/kg developed varices, a 43.2% reduction ( p =0.13). In the per-protocol population (PP), varices occurred in 22.3% with placebo versus 11.3% with belapectin 2 mg/kg, a 50% reduction (unadjusted p =0.04). Belapectin 4 mg/kg had no significant effect on variceal development. For the composite endpoint at 18 months, no significant difference was observed between belapectin 2 mg/kg ( p =0.14) or 4 mg/kg ( p =0.261) and placebo in the FAS. Belapectin was well-tolerated with no safety signals. Conclusion: Belapectin 2 mg/kg lowered the development of new varices in MASH cirrhosis and portal hypertension. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Galectin Inhibitor: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Galectin Inhibitor (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Galectin%20Inhibitor\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Galectin Inhibitor\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Galectin%20Inhibitor\"}]}}"}}]],["$","$L2f",null,{"title":"Galectin Inhibitor: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Galectin Inhibitor — concise summaries and practical next steps.","papers":[{"doi":"10.1182/blood.2025032631","pmid":"42345360","title":"Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-06-23T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025032631","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-29T13:22:48.475Z","updated_at":"2026-06-29T13:22:48.475Z","tags":[{"paper_doi":"10.1182/blood.2025032631","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"brand","value":"OTX008","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"condition","value":"Essential Thrombocythemia","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"condition","value":"Myelofibrosis","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"condition","value":"Myeloproliferative Neoplasm","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"condition","value":"Polycythemia Vera","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"generic","value":"galectin-1 inhibitor OTX008","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"modality","value":"Galectin Inhibitor","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"sample_size","value":"n=34","value_numeric":34},{"paper_doi":"10.1182/blood.2025032631","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"study_design","value":"Translational Study (scRNA-seq, CyTOF, In Vitro, In Vivo Mouse Model)","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"warning","value":"Sample size for human plasma ELISA (n=34 MPN, n=7 HI) is small; subgroup analyses by MPN subtype (PV n=8, ET n=13, MF n=13) are underpowered.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"warning","value":"Study design is predominantly preclinical and translational; no randomized clinical trial data are included — 'practice_changing' impact flag reflects novelty of therapeutic target, not clinical trial evidence.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"warning","value":"Study design tag reflects a multi-method translational study; no single canonical design label applies cleanly.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032631","tag_type":"warning","value":"TLR4–Gal-1 protein interaction is inferred by computational docking and co-immunoprecipitation only; direct structural confirmation is lacking.","value_numeric":null}],"summaries":{"what_studied":"This study investigated the role of galectin-1 (Gal-1/LGALS1) in monocyte-driven inflammation in myeloproliferative neoplasms (MPNs), using scRNA-seq, CyTOF, and functional assays in human MPN samples (n=34 patients) and a MPLW515L murine transplant model, with Lgals1 genetic knockout and pharmacological inhibition (OTX008).","key_result":"Gal-1 was elevated in MPN monocytes and plasma (vs. healthy controls, n=7 HI vs. n=34 MPN by ELISA); recombinant Gal-1 markedly increased inflammatory cytokine transcription and secretion in CD14+ MPN monocytes via TLR4/NF-κB signaling; Lgals1 knockout in the MPLW515L mouse model ameliorated leukocytosis and splenomegaly, and Gal-1 inhibition suppressed carrageenan-induced thrombosis and inflammation in vivo.","limitations":"- Murine MPLW515L transplant model may not fully recapitulate human MPN biology.\n- Human cohort is relatively small (n=34 MPN), limiting generalizability across MPN subtypes and mutational contexts.\n- Mechanistic TLR4–Gal-1 interaction is supported by computational docking and co-immunoprecipitation but lacks structural confirmation (e.g., crystallography).","practice_takeaway":"Gal-1 drives monocyte hyperinflammation in MPNs through TLR4/NF-κB signaling and may represent a druggable target; the Gal-1 inhibitor OTX008 warrants clinical investigation in MPN, particularly for patients with high monocyte counts or inflammatory burden."}},{"doi":"10.1097/hep.0000000000001774","pmid":"42065864","title":"Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial","journal_title":"Hepatology","journal_issn":"0270-9139","published_at":"2026-05-01T00:00:00.000Z","url":"https://doi.org/10.1097/hep.0000000000001774","source_score":23,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-08","doi":"10.1097/hep.0000000000001774","days":"7","issn":"0270-9139","rank":"4","field":"Clinical Medicine","score":"23","category":"Gastroenterology & Hepatology","categories":["Gastroenterology & Hepatology"],"_categories":["Gastroenterology & Hepatology"]},"pubmed":{"doi":"10.1097/HEP.0000000000001774","title":"Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial.","journal":"Hepatology (Baltimore, Md.)","methods":"","results":"","abstract":"$30","keywords":["MASLD","cirrhosis","metabolic dysfunction–associated steatohepatitis","portal hypertension","safety","varices"],"pubmed_id":"42065864","conclusions":"Belapectin 2 mg/kg lowered the development of new varices in MASH cirrhosis and portal hypertension.","publication_date":"2026-05-01T00:00:00"},"crossref":{"DOI":"10.1097/hep.0000000000001774","URL":"https://doi.org/10.1097/hep.0000000000001774","ISSN":["0270-9139","1527-3350"],"link":[{"URL":"https://journals.lww.com/10.1097/HEP.0000000000001774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial"],"author":[{"given":"Naga","family":"Chalasani","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, USA"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, Indiana, USA"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[{"name":"Houston Methodist Hospital and Houston Research Institute, Houston, Texas, USA"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[{"name":"Liver Institute of Virginia, Richmond, Virginia, USA"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[{"name":"Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, USA"}]},{"given":"Edward","family":"Mena","sequence":"additional","affiliation":[{"name":"California Liver Research Institute, Pasadena, California, USA"}]},{"given":"Nadege T.","family":"Gunn","sequence":"additional","affiliation":[{"name":"Coryell Health Medical Clinic, Waco, Texas, USA"}]},{"given":"Laura","family":"Ladron de Guevara","sequence":"additional","affiliation":[{"name":"Center of Research and Gastroenterology, Mexico City, Mexico"}]},{"given":"Hesham","family":"Elgouhari","sequence":"additional","affiliation":[{"name":"Texoma Liver Center, Denison, Texas, USA"}]},{"given":"Rifaat","family":"Safadi","sequence":"additional","affiliation":[{"name":"Hadassah Medical Centers of Hebrew University, Jerusalem, Israel"}]},{"given":"Khurram","family":"Jamil","sequence":"additional","affiliation":[{"name":"Galectin Therapeutics, Atlanta, Georgia, USA"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Summit Clinical Research, San Antonio, Texas, USA"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[{"name":"Summit Clinical Research and North Shore Gastroenterology, Cleveland, Ohio, USA"}]}],"issued":{"date-parts":[[2026,5,1]]},"member":"276","prefix":"10.1097","source":"Crossref","volume":null,"created":{"date-time":"2026-05-01T16:00:09Z","timestamp":1777651209000,"date-parts":[[2026,5,1]]},"indexed":{"date-time":"2026-05-12T11:08:36Z","timestamp":1778584116878,"date-parts":[[2026,5,12]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc-nd/4.0/","start":{"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000,"date-parts":[[2026,5,1]]},"delay-in-days":0,"content-version":"unspecified"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://journals.lww.com/10.1097/HEP.0000000000001774"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","value":"2026-02-25"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","value":"2026-04-02"}],"deposited":{"date-time":"2026-05-12T10:14:36Z","timestamp":1778580876000,"date-parts":[[2026,5,12]]},"issn-type":[{"type":"print","value":"0270-9139"},{"type":"electronic","value":"1527-3350"}],"published":{"date-parts":[[2026,5,1]]},"publisher":"Ovid Technologies (Wolters Kluwer Health)","reference":[{"DOI":"10.1016/j.aohep.2023.101133","key":"R1-20260512","year":"2024","issue":null,"author":"Rinella","volume":"29","first-page":"101133","unstructured":null,"article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","journal-title":"Ann Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.tem.2024.02.007","key":"R2-20260512","year":"2024","issue":null,"author":"Miao","volume":"35","first-page":"697","unstructured":null,"article-title":"Current status and future trends of the global burden of MASLD","journal-title":"Trends Endocrinol Metab","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2468-1253(22)00165-0","key":"R3-20260512","year":"2022","issue":null,"author":"Riazi","volume":"7","first-page":"851","unstructured":null,"article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","journal-title":"Lancet Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.aohep.2023.101154","key":"R4-20260512","year":"2024","issue":null,"author":"Wang","volume":"29","first-page":"101154","unstructured":null,"article-title":"Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011–2018","journal-title":"Ann Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1097/HEP.0000000000000004","key":"R5-20260512","year":"2023","issue":null,"author":"Younossi","volume":"77","first-page":"1335","unstructured":null,"article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","journal-title":"Hepatology","doi-asserted-by":"crossref"},{"DOI":null,"key":"R6-20260512","year":"2023","issue":null,"author":"Younossi","volume":"8","first-page":"e0352","unstructured":null,"article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013–2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","journal-title":"Hepatol Commun","doi-asserted-by":null},{"DOI":"10.1111/liv.70001","key":"R7-20260512","year":"2025","issue":null,"author":"Tham","volume":"45","first-page":"e70001","unstructured":null,"article-title":"The global burden of cirrhosis and other chronic liver diseases in 2021","journal-title":"Liver Int","doi-asserted-by":"crossref"},{"DOI":"10.1111/apt.18451","key":"R8-20260512","year":"2025","issue":null,"author":"Owrangi","volume":"61","first-page":"433","unstructured":null,"article-title":"Meta-analysis: Global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease","journal-title":"Aliment Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2021.11.014","key":"R9-20260512","year":"2023","issue":null,"author":"Yong","volume":"21","first-page":"45","unstructured":null,"article-title":"Outcomes of nonalcoholic steatohepatitis after liver transplantation: An updated meta-analysis and systematic review","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1080/00365521.2023.2175619","key":"R10-20260512","year":"2023","issue":null,"author":"de Wit","volume":"58","first-page":"900","unstructured":null,"article-title":"Decompensation as initial presentation in patients with liver cirrhosis is associated with an increased risk of future decompensation and mortality","journal-title":"Scand J Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1097/HEP.0000000000001243","key":"R11-20260512","year":"2025","issue":null,"author":"Younossi","volume":"82","first-page":"1229","unstructured":null,"article-title":"Prevalence and predictors of cirrhosis and portal hypertension in the United States","journal-title":"Hepatology","doi-asserted-by":"crossref"},{"DOI":"10.1097/HC9.0000000000000682","key":"R12-20260512","year":"2025","issue":null,"author":"Brown","volume":"9","first-page":"e0682","unstructured":null,"article-title":"Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives","journal-title":"Hepatol Commun","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmjgast-2023-001234","key":"R13-20260512","year":"2023","issue":null,"author":"Lee","volume":"10","first-page":"e001234","unstructured":null,"article-title":"Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: A retrospective observational cohort study","journal-title":"BMJ Open Gastroenterol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhepr.2023.100809","key":"R14-20260512","year":"2023","issue":null,"author":"Pennisi","volume":"5","first-page":"100809","unstructured":null,"article-title":"Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease","journal-title":"JHEP Rep","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMra0901512","key":"R15-20260512","year":"2010","issue":null,"author":"Garcia-Tsao","volume":"362","first-page":"823","unstructured":null,"article-title":"Management of varices and variceal hemorrhage in cirrhosis","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1093/gastro/gox007","key":"R16-20260512","year":"2017","issue":null,"author":"Haq","volume":"5","first-page":"113","unstructured":null,"article-title":"Recent advances in the management of variceal bleeding","journal-title":"Gastroenterol Rep (Oxf)","doi-asserted-by":"crossref"},{"DOI":"10.1021/bi201121m","key":"R17-20260512","year":"2011","issue":null,"author":"Di Lella","volume":"50","first-page":"7842","unstructured":null,"article-title":"When galectins recognize glycans: From biochemistry to physiology and back again","journal-title":"Biochemistry","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0075361","key":"R18-20260512","year":"2013","issue":null,"author":"Traber","volume":"8","first-page":"e75361","unstructured":null,"article-title":"Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0083481","key":"R19-20260512","year":"2013","issue":null,"author":"Traber","volume":"8","first-page":"e83481","unstructured":null,"article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1111/apt.13816","key":"R20-20260512","year":"2016","issue":"11–12","author":"Harrison","volume":"44","first-page":"1183","unstructured":null,"article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","journal-title":"Aliment Pharmacol Ther","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2019.11.296","key":"R21-20260512","year":"2020","issue":null,"author":"Chalasani","volume":"158","first-page":"1334","unstructured":null,"article-title":"Belapectin (GR-MD-02) Study Investigators. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2020.04.039","key":"R22-20260512","year":"2020","issue":null,"author":"Noureddin","volume":"159","first-page":"422","unstructured":null,"article-title":"Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations from the Multi-stakeholder Liver Forum","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1111/dom.16142","key":"R23-20260512","year":"2025","issue":null,"author":"Malandris","volume":"27","first-page":"1406","unstructured":null,"article-title":"Diagnostic accuracy of Agile-4 score for liver cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease. A systematic review and meta-analysis of diagnostic test accuracy studies","journal-title":"Diabetes Obes Metab","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2022.10.034","key":"R24-20260512","year":"2023","issue":null,"author":"Sanyal","volume":"78","first-page":"247","unstructured":null,"article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores","journal-title":"J Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2024.05.021","key":"R25-20260512","year":"2024","issue":null,"author":"Papatheodoridi","volume":"81","first-page":"590","unstructured":null,"article-title":"Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms","journal-title":"J Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2021.12.022","key":"R26-20260512","year":"2022","issue":null,"author":"de Franchis","volume":"76","first-page":"959","unstructured":null,"article-title":"Faculty. Baveno VII - Renewing consensus in portal hypertension","journal-title":"J Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1002/sim.2335","key":"R27-20260512","year":"2006","issue":null,"author":"Liu","volume":"25","first-page":"1275","unstructured":null,"article-title":"Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials","journal-title":"Stat Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2024.05.008","key":"R28-20260512","year":"2024","issue":null,"author":"Gawrieh","volume":"81","first-page":"600","unstructured":null,"article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","journal-title":"J Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1136/gutjnl-2022-327777","key":"R29-20260512","year":"2023","issue":null,"author":"Loomba","volume":"72","first-page":"581","unstructured":null,"article-title":"Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2020.06.045","key":"R30-20260512","year":"2021","issue":null,"author":"Petta","volume":"19","first-page":"806","unstructured":null,"article-title":"Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2023.06.030","key":"R31-20260512","year":"2023","issue":null,"author":"Semmler","volume":"165","first-page":"1041","unstructured":null,"article-title":"Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1136/gut.2005.069153","key":"R32-20260512","year":"2006","issue":null,"author":"Foucher","volume":"55","first-page":"403","unstructured":null,"article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study","journal-title":"Gut","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhepr.2024.101062","key":"R33-20260512","year":"2024","issue":null,"author":"Pearson","volume":"6","first-page":"101062","unstructured":null,"article-title":"Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality","journal-title":"JHEP Rep","doi-asserted-by":"crossref"},{"DOI":"10.1111/liv.12896","key":"R34-20260512","year":"2016","issue":null,"author":"Irvine","volume":"36","first-page":"370","unstructured":null,"article-title":"The enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease","journal-title":"Liver Int","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cgh.2020.06.070","key":"R35-20260512","year":"2021","issue":null,"author":"Are","volume":"19","first-page":"1292","unstructured":null,"article-title":"Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis","journal-title":"Clin Gastroenterol Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2013.03.016","key":"R36-20260512","year":"2013","issue":null,"author":"Lichtinghagen","volume":"59","first-page":"236","unstructured":null,"article-title":"The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values","journal-title":"J Hepatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"R37-20260512","year":"2025","issue":null,"author":"Sanyal","volume":null,"first-page":null,"unstructured":null,"article-title":"Primary prevention of bleeding from esophageal varices in patients with cirrhosis","journal-title":"Up-to-Date","doi-asserted-by":null},{"DOI":"10.1371/journal.pone.0313152","key":"R38-20260512","year":"2025","issue":null,"author":"Mohammadi","volume":"20","first-page":"e0313152","unstructured":null,"article-title":"Disease trajectory and competing risks of patients with cirrhosis in the US","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1053/j.gastro.2013.10.018","key":"R39-20260512","year":"2014","issue":null,"author":"Reverter","volume":"146","first-page":"412","unstructured":null,"article-title":"A MELD-based model to determine risk of mortality among patients with acute variceal bleeding","journal-title":"Gastroenterology","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhepr.2019.12.001","key":"R40-20260512","year":"2019","issue":null,"author":"Rodrigues","volume":"2","first-page":"100063","unstructured":null,"article-title":"Beta-blockers in cirrhosis: Evidence-based indications and limitations","journal-title":"JHEP Rep","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2018.03.024","key":"R41-20260512","year":"2018","issue":null,"author":null,"volume":"69","first-page":"406","unstructured":null,"article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","journal-title":"J Hepatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jhep.2021.03.003","key":"R42-20260512","year":"2021","issue":null,"author":"Putera","volume":"75","first-page":"491","unstructured":null,"article-title":"Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?","journal-title":"J Hepatol","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1097/lww.0000000000001000","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Hepatology"],"reference-count":42,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,1]]},"references-count":42,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1097/hep.0000000000001774","is_oa":false,"title":"Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial","updated":"2026-05-06T13:23:02+00:00","published_date":"2026-05-01","best_oa_location":null}},"created_at":"2026-05-13T13:19:31.960Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"condition","value":"Esophageal Varices","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"condition","value":"MASH Cirrhosis","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"condition","value":"Portal Hypertension","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"generic","value":"belapectin","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"modality","value":"Galectin Inhibitor","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"sample_size","value":"n=357","value_numeric":357},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"warning","value":"Brand name for belapectin was not mentioned in the abstract; no brand tag applied.","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"warning","value":"The full text body provided in the paper was a GI society statement on racism and social injustice, not the NAVIGATE trial manuscript — structured data were extracted solely from the abstract. Granular methodology, subgroup analyses, and safety details could not be verified from the full text.","value_numeric":null},{"paper_doi":"10.1097/hep.0000000000001774","tag_type":"warning","value":"The per-protocol population result (p=0.04) was a secondary/pre-specified analysis; the primary FAS endpoint did not achieve statistical significance (p=0.13). Impact flag set to 'limited_evidence' accordingly.","value_numeric":null}],"summaries":{"what_studied":"The NAVIGATE trial evaluated belapectin (2 mg/kg or 4 mg/kg IV lean body weight) versus placebo over 18 months for prevention of esophageal varices in patients with MASH cirrhosis and portal hypertension who had no varices at baseline (n=357 randomized).","key_result":"In the per-protocol population, belapectin 2 mg/kg reduced new variceal development by 50% vs. placebo (11.3% vs. 22.3%; unadjusted p=0.04). In the full analysis set, the reduction was 43.2% (10.1% vs. 17.8%) but did not reach significance (p=0.13). Belapectin 4 mg/kg showed no significant effect. The composite endpoint was not significantly different in either dose arm.","limitations":"- Primary endpoint in the full analysis set (FAS) did not reach statistical significance; the 50% reduction was only significant in the per-protocol population, a secondary analysis.\n- Phase 2b trial; underpowered to confirm efficacy definitively.\n- The full text provided was largely a GI society statement unrelated to the trial, limiting extraction of granular methodology and subgroup data.","practice_takeaway":"Belapectin 2 mg/kg may reduce new esophageal varix formation in MASH cirrhosis with portal hypertension, but results are not yet practice-changing — the primary endpoint missed significance. Clinicians should await phase 3 data before adopting this agent."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Galectin Inhibitor"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Galectin Inhibitor"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Galectin Inhibitor"}}}]]

Papers